Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT03987763
PHASE4

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

Sponsor: Bausch Health Americas, Inc.

View on ClinicalTrials.gov

Summary

This study is to evaluate the safety, the systemic exposure of halobetasol propionate (HP), and the hypothalamic-pituitary-adrenal (HPA) axis suppression potential for topically applied IDP-122 lotion in pediatric participants with moderate to severe plaque psoriasis.

Official title: A Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Key Details

Gender

All

Age Range

6 Years - 17 Years

Study Type

INTERVENTIONAL

Enrollment

45

Start Date

2019-10-22

Completion Date

2026-06

Last Updated

2025-08-27

Healthy Volunteers

No

Conditions

Interventions

DRUG

IDP-122 Lotion

Topical

Locations (9)

Bausch Site 11

Fountain Valley, California, United States

Bausch Site 2

Thousand Oaks, California, United States

Bausch Site 07

Doral, Florida, United States

Bausch Site 3

Miami, Florida, United States

Bausch Site 06

Miami, Florida, United States

Bausch Site 05

Spartanburg, South Carolina, United States

Bausch Site 1

Spokane, Washington, United States

Bausch Site 12

Santo Domingo, Dominican Republic

Bausch Site 4

Panama City, Panama